Padova, Italy and Utrecht, the Netherlands, April 24th, 2018

The Istituto Oncologico Veneto (IOV) has acquired MILabs’ latest generation VECTor5CT as a key imaging tool to support its translational oncology mission, entrusted by the Italian Ministry of Health and the Organization of the European Cancer Institutes. Due to its high-resolution imaging capabilities, MILabs’ preclinical Versatile Emission Computed Tomography system (“VECTor”) is very well suited to enable a quick translation of molecular research from the bench to the clinic at the IOV. 

According to Prof. Antonio Rosato, Deputy Scientific Director and in charge of the preclinical imaging facility of the Institute: “We anticipate that the unique ability of the MILabs system to image tumors with high-definition PET, SPECT and CT modalities, further enhanced by high-resolution imaging of radiotherapeutic tracers such as 188Re, will accelerate IOV’s research on the personalization of therapy in solid tumors”.

Prof. Freek Beekman, CEO/CSO of MILabs B.V. adds: “We are confident that the unique diagnostic and theranostic imaging capabilities of the VECTor5CT will help IOV-IRCCS stay at the leading edge of bringing the latest scientific findings from the laboratory to the patient so it can keep offering the most innovative therapies”.

By integrating multiple modalities on a single system, MILabs’ VECTor PET/SPECT/CT enables to expand diagnostic and treatment applications beyond the capabilities of any other preclinical imaging system including single-pass simultaneous PET and SPECT, dynamic molecular CT acquisitions as well as theranostic imaging with alpha- and beta- radiotherapy nuclides.

About the Istituto Oncologico Veneto (IOV):

The Veneto Institute of Oncology (IOV), located in Padova is the first institute in the north-eastern region of Italy specifically created for cancer prevention, diagnosis, and cure, and focused on cancer research. The IOV has established itself as a research hospital of high specialization and a health research center of national and international importance. It is recognized by the Ministry of Health as an Institute of Hospitalization and Scientific Care (IRCCS) and by the Organization of European Cancer Institutes (OECI) as a Comprehensive Cancer Center. The institute’s research is focused on exploiting the synergy between biomedical research and clinical research in order to reduce the time between disease target identification and clinically relevant therapeutic intervention. More info at

About MILabs B.V.:

MILabs B.V. (Utrecht, the Netherlands) provides high-end integrated multimodality imaging solutions for biomedical and pharmaceutical research, designed to deliver high-definition molecular, functional and anatomical images. Today these systems contribute worldwide to the development of new diagnostic solutions and therapies for diseases such as diabetes, cancer, cardiac and neurodegenerative diseases. For more information, visit or contact MILabs at [email protected]